TY - JOUR
T1 - Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia
T2 - patient views
AU - Tromp, Vashti N.M.F.
AU - Timmers, Lonneke
AU - Koningen, Leanne
AU - Janssen, Jeroen J.W.M.
AU - Westerweel, Peter E.
AU - Geelen, Inge G.P.
AU - de Jong, Jan
AU - Beckeringh, Jan J.
AU - Boons, Christel C.L.M.
AU - Hugtenburg, Jacqueline G.
N1 - Funding Information: The authors thank the patients who completed the questionnaire, the hospital outpatient pharmacies for their cooperation and the Hematon patient association for sharing the web link to the questionnaire with their members. The authors thank the patients who pre-tested the questionnaire. Publisher Copyright: © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Patients with chronic myeloid leukemia (CML) in deep molecular remission may discontinue tyrosine kinase inhibitor (TKI) treatment without relapse. The present study aims to gain insight into the views of CML patients on TKI treatment discontinuation and identify factors that are associated with their willingness to discontinue treatment. A cross-sectional study, among adult Dutch CML patients was conducted to assess willingness and their views on benefits of and concerns about discontinuation. A total of 185 patients participated of whom 76% were willing to discontinue TKI-treatment. Patients considered the absence of side effects the most important benefit whereas fear of disease recurrence was their most prominent concern. Adequate monitoring was the most important prerequisite for TKI-treatment discontinuation. However, ambiguity with respect to perquisites indicate that patients on long-term TKI treatment should be adequately informed both on the possibility to discontinue treatment and on its benefits, risks, and measures that address risks.
AB - Patients with chronic myeloid leukemia (CML) in deep molecular remission may discontinue tyrosine kinase inhibitor (TKI) treatment without relapse. The present study aims to gain insight into the views of CML patients on TKI treatment discontinuation and identify factors that are associated with their willingness to discontinue treatment. A cross-sectional study, among adult Dutch CML patients was conducted to assess willingness and their views on benefits of and concerns about discontinuation. A total of 185 patients participated of whom 76% were willing to discontinue TKI-treatment. Patients considered the absence of side effects the most important benefit whereas fear of disease recurrence was their most prominent concern. Adequate monitoring was the most important prerequisite for TKI-treatment discontinuation. However, ambiguity with respect to perquisites indicate that patients on long-term TKI treatment should be adequately informed both on the possibility to discontinue treatment and on its benefits, risks, and measures that address risks.
KW - Chronic myeloid leukemia
KW - patient views
KW - treatment discontinuation
KW - tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85095738302&partnerID=8YFLogxK
U2 - https://doi.org/10.1080/10428194.2020.1839655
DO - https://doi.org/10.1080/10428194.2020.1839655
M3 - Article
C2 - 33153332
SN - 1042-8194
VL - 62
SP - 649
EP - 658
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 3
ER -